Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose‐seeking study

Cancer

Volumn 74, Issue 11, 1994, Pages 2949-2955

  Glover, Donna ^a   Lipton, Alan ^b   Keller, Alan ^c   Miller, Antonius A ^d   Browning, Scott ^e   Fram, Robert J ^f,i   George, Sebastian ^g   Zelenakas, Kenneth ^h   Macerata, Richard S ^h   Seaman, John J ^h  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c The University of Tennessee ^*  (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e KAISER PERMANENTE   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g Cancer and Blood Inst of the Desert   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

bone metastases; bone pain; breast cancer; pamidronate

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; CREATININE; HYDROMORPHONE; HYDROXYPROLINE; MORPHINE SULFATE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCALCIN; PAMIDRONIC ACID; PERCOCET; PIROXICAM; TAMOXIFEN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALGESIA; ARTICLE; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; BREAST CANCER; CALCIUM URINE LEVEL; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MYALGIA; PAIN ASSESSMENT; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANALGESICS, OPIOID; BONE NEOPLASMS; BREAST NEOPLASMS; CALCIUM; CREATININE; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; HYDROXYPROLINE; INFUSIONS, INTRAVENOUS; MIDDLE AGE; PAIN; PALLIATIVE CARE; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T;

EID: 0027949284     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q     Document Type: Article

References (16)

1. Bone metastases and breast cancer
2. Pathology of metastatic tumors in bone
3. The role of bone and kidney in tumor‐induced hypercalcemia and its treatment with bisphosphonate and sodium chloride
4. Single versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy
5. Single dose intravenous therapy with pamidronate (APD) for the treatment of hypercalcemia of malignancy: comparison of 30, 60, and 90 mg dosages
6. A new diphosphonate: dissociation between effects on cells and mineral in rats and a preliminary trial in Paget's disease
7. Kinetic studies of bone and mineral metabolism during treatment with (3‐amino‐1‐hydroxypropylidene)‐1, 1‐bisphosphonate (APD) in rats
8. Quantitative morphometric evaluation of the inhibitory activity of new amino‐bisphos‐phonates on bone resorption in the rat
9. Inhibition of osteolytic bone lesions by (3‐amino‐1‐hydroxypropylidene)‐1, 1‐bisphosphonate (APD)
10. Treatment of bone metastases from breast cancer and myeloma with pamidronate
11. Treatment of bone metastases from breast cancer with (3‐amino‐1‐hydroxypropylidene)‐1, 1 bisphosphonate (APD)
12. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma
13. The palliation of symptomatic osseous metastases
14. Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins
15. Pain syndromes in patients with cancer
16. Reduced morbidity from skeletal metastases in breast cancer patients during long‐term bisphosphonate (APD) treatment